COTA expands clinicogenomics offering with Genomic Testing Cooperative partnership.

Research matters

When you’re focusing on the future of cancer care, it helps to start with a clear and accurate picture of the present.

Article
MORE →
Abstract
MORE →
Abstract
MORE →
Abstract
MORE →
Abstract
MORE →
Prapti A. Patel, Yazan F. Madanat, Andrew J. Belli, Eric Hansen, Heidi Foss, Molly Schulte, Ching-Kun Wang
We investigated the outcomes of patients treated with venetoclax based combination therapies in a large cohort of patients in the real-world setting. Survival differences were observed in the different treatment arms with Ven/LDAC having the shortest OS and ven/dac and ven/HMA having comparable survival rates.

Subscribe for Updates

Receive our latest news and research from thought leaders in the RWD industry
  • This field is for validation purposes and should be left unchanged.